Cocrystal Pharma, Inc.— Sankey Diagram
Quarterly mode · period ending 2020-12-31 · SEC EDGAR
ComparingFY2020 (Q4) vs FY2019 (Q4)
Revenue
$510K
↑+26.9% +$108Kvs FY2019 (Q4)
Gross Profit
$510K
↑+26.9% +$108Kvs FY2019 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2020 (Q4) | FY2019 (Q4) |
|---|---|---|
| Revenue | $510K | $402K |
| COGS | $0 | $0 |
| Gross Profit | $510K | $402K |
| R&D | $698K | $958K |
| SG&A | $0 | $0 |
| D&A | $45K | $29K |
| Other OpEx | $0 | $0 |
| Operating Income | $0 | $0 |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $0 | $0 |
| Tax | $0 | $0 |
| Net Income | $0 | $0 |
QuarterCharts · SEC EDGAR data · COCP · Comparing FY2020 (Q4) vs FY2019 (Q4)